Mark Pegram

15PUBLICATIONS
68CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Economic models and forecastingPredictive and prognostic markersCounselling, wellbeing and community services
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 09, 2026
Beyond amplification: precision approaches to targeting HER2.

|Dec 09, 2025
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Xiaosong Chen, Jiahui Huang, Haoting Shi

|Nov 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Hope S Rugo, Virginia Kaklamani, Heather McArthur

|Nov 18, 2023
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.

Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam

|Jun 28, 2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.

Giuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac

|May 31, 2023
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.

Mark Pegram, Christian Jackisch, Stephen R D Johnston

Pageof 3

Frequent Collaborators

4 joint publications

Nancy U Lin

3 joint publications

Nuhad Ibrahim

2 joint publications

William J Gradishar

2 joint publications

Whitney Kirschbrown